Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation

Biochemical and Biophysical Research Communications

Volumn 433, Issue 4, 2013, Pages 374-378

  Kato, Yukinari ^a   Kaneko, Mika Kato ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

IDH2 mutation; Monoclonal antibody; R172W

Indexed keywords

ISOCITRATE DEHYDROGENASE 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY WMAB 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; CELL CULTURE; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; HYBRIDOMA; IMMUNOCYTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; ESCHERICHIA COLI; GLIOBLASTOMA; GLIOMA; HYBRIDOMAS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MICE; MUTATION; PEPTIDE FRAGMENTS; RATS; RATS, INBRED WKY; RECOMBINANT PROTEINS; TRANSFECTION;

RATTUS;

EID: 84876498207     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.02.106     Document Type: Article

References (24)

1. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
2. Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., Tominaga T. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009, 100:1996-1998.
3. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J.W., Wesseling P., Reifenberger G., von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009, 118:469-474.
4. Pansuriya T.C., van Eijk R., d'Adamo P., van Ruler M.A., Kuijjer M.L., Oosting J., Cleton-Jansen A.M., van Oosterwijk J.G., Verbeke S.L., Meijer D., van Wezel T., Nord K.H., Sangiorgi L., Toker B., Liegl-Atzwanger B., San-Julian M., Sciot R., Limaye N., Kindblom L.G., Daugaard S., Godfraind C., Boon L.M., Vikkula M., Kurek K.C., Szuhai K., French P.J., Bovee J.V. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat. Genet. 2011, 43:1256-1261.
5. Amary M.F., Damato S., Halai D., Eskandarpour M., Berisha F., Bonar F., McCarthy S., Fantin V.R., Straley K.S., Lobo S., Aston W., Green C.L., Gale R.E., Tirabosco R., Futreal A., Campbell P., Presneau N., Flanagan A.M. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat. Genet. 2011, 43:1262-1265.
6. Amary M.F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., Pollock R., O'Donnell P., Grigoriadis A., Diss T., Eskandarpour M., Presneau N., Hogendoorn P.C., Futreal A., Tirabosco R., Flanagan A.M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 2011, 224:334-343.
7. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
8. Chotirat S., Thongnoppakhun W., Promsuwicha O., Boonthimat C., Auewarakul C.U. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J. Hematol. Oncol. 2012, 5:5.
9. Gross S., Cairns R.A., Minden M.D., Driggers E.M., Bittinger M.A., Jang H.G., Sasaki M., Jin S., Schenkein D.P., Su S.M., Dang L., Fantin V.R., Mak T.W. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 2010, 207:339-344.
10. Takano S., Kato Y., Yamamoto T., Kaneko M.K., Ishikawa E., Tsujimoto Y., Matsuda M., Nakai K., Yanagiya R., Morita S., Tsuboi K., Matsumura A. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J. Neurooncol. 2012, 108:361-373.
11. Kaneko M.K., Tian W., Takano S., Suzuki H., Sawa Y., Hozumi Y., Goto K., Yamazaki K., Kitanaka C., Kato Y. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem. Biophys. Res. Commun. 2011, 406:608-613.
12. Kato Y., Jin G., Kuan C.T., McLendon R.E., Yan H., Bigner D.D. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem. Biophys. Res. Commun. 2009, 390:547-551.
13. Capper D., Zentgraf H., Balss J., Hartmann C., von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009, 118:599-601.
14. Kaneko M.K., Morita S., Tsujimoto Y., Yanagiya R., Nasu K., Sasaki H., Hozumi Y., Goto K., Natsume A., Watanabe M., Kumabe T., Takano S., Kato Y. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem. Biophys. Res. Commun. 2013, 432:40-45.
15. Kato Y., Natsume A., Kaneko M.K. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem. Biophys. Res. Commun. 2013, 432:564-567.
16. Takano S., Tian W., Matsuda M., Yamamoto T., Ishikawa E., Kaneko M.K., Yamazaki K., Kato Y., Matsumura A. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011, 28:115-123.
17. Motomura K., Natsume A., Watanabe R., Ito I., Kato Y., Momota H., Nishikawa R., Mishima K., Nakasu Y., Abe T., Namba H., Nakazato Y., Tashiro H., Takeuchi I., Mori T., Wakabayashi T. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci. 2012, 103:1871-1879.
18. Kwon M.J., Kim S.T., Kong D.S., Lee D., Park S., Kang S.Y., Song J.Y., Nam D.H., Kato Y., Choi Y.L., Suh Y.L. Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri. Brain Pathol. 2012, 22:307-317.
19. Yoshikawa A., Nakada M., Watanabe T., Hayashi Y., Sabit H., Kato Y., Suzuki S., Ooi A., Sato H., Hamada J.I. Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation. Brain Tumor Pathol. 2012, 10.1007/s10014-012-0118-9.
20. Kato Y., Kaneko M.K., Kuno A., Uchiyama N., Amano K., Chiba Y., Hasegawa Y., Hirabayashi J., Narimatsu H., Mishima K., Osawa M. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 2006, 349:1301-1307.
21. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.L., Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
22. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
23. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116:597-602.
24. M.K. Kaneko, Y. Tsujimoto, Y. Hozumi, K. Goto, Y. Kato, Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations, Monoclon. Antib. Immunodiagn. Immunother., in press.